University of Tampere   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tampere Finland (1925)

Organization Overview

First Clinical Trial
1994
NCT00966264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Arvi Yli-Hankala | Center for Child Health Research, Tampere University | Department of Intensive Care, Tampere UH | Department of Psychology, University of Tampere, Finland | Elina Brinck | Gynecologi - Ja Urologikeskus - Tampere - Finland | Heart Center Co. Tampere university hospital | Heart Hospital of Tampere University Hospital | Ja Urologikeskus, Tampere, Finland | Medical Research Fund of the Tampere University Hospital, Finland | Medical School, University of Tampere and Tampere University Hospital | Obstetrics and Gynecology Unit: Tampere University Hospital | Pirkko-Liisa Kellokumpu-Lehtinen | PROF EMER, UNIVERSITY OF TAMPERE | Tampere UH | Tampere University | Tampere University Central Hospital, Finland | Tampere University Hospital | Tampere University Hospital, Department of Anesthesia | Tampere University Hospital, Finland | Tampere University Hospital Heart Center | Tampere University Hospital, Kuopio University Hospital | Tampere University Hospital, Tampere University | University of Tampere | University of Tampere, Finland | University of Tampere Medical School | University of Tampere, Medical School | University of Tampere Medical School, Finland | University of Tampere, School of Public Health | University of Tampere Vaccine Research Clinic | Unversity Hospital of Tampere, Finland

Active Ingredients

Drugs in Phase 4 Trials (54)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (2 trials)

acetylsalicylic acid (aspirin) (2 trials)

albuterol (proventil) (1 trial)

aminolevulinic acid (levulan) (3 trials)

amiodarone (cordarone) (1 trial)

bicalutamide (casodex) (1 trial)

budesonide (rhinocort) (1 trial)

collagenase clostridium histolyticum (xiaflex) (1 trial)

cow milk (1 trial)

cyanocobalamin (berocca) (1 trial)

desflurane (suprane) (1 trial)

dexamethasone (2 trials)

dexmedetomidine (precedex) (2 trials)

dopamine (intropin) (1 trial)

enoxaparin (lovenox) (3 trials)

escherichia coli nissle 1917 (1 trial)

fluorouracil (efudex) (1 trial)

formoterol (foradil) (1 trial)

glucose (1 trial)

glycopyrronium (robinul) (1 trial)

goserelin (zoladex) (2 trials)

human choriogonadotropin alfa (hCG) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

hydroxyethyl starch (voluven) (1 trial)

imatinib (gleevec) (1 trial)

infliximab (remicade) (2 trials)

insulin lispro (humalog) (1 trial)

ketamine (ketalar) (1 trial)

levosimendan (2 trials)

metformin (glucophage) (1 trial)

methyl aminolevulinate (metvixia) (2 trials)

metoprolol (lopressor) (1 trial)

misoprostol (cytotec) (1 trial)

naloxone (narcan) (1 trial)

naltrexone (revia) (2 trials)

neostigmine (bloxiverz) (2 trials)

norepinephrine (levophed) (1 trial)

oxycodone (oxycontin) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

prednisone (meticorten) (2 trials)

propofol (diprivan) (1 trial)

remdesivir (Veklury) (1 trial)

rocuronium (zemuron) (1 trial)

ropivacaine (naropin) (3 trials)

rupatadine (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (9 trials)

sugammadex (bridion) (1 trial)

sulfasalazine (azulfidine) (2 trials)

tafluprost (zioptan) (2 trials)

tinzaparin (Innohep) (1 trial)

triamcinolone (kenalog) (1 trial)

triptorelin (Trelstar) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 3 Trials (18)

atorvastatin (lipitor) (3 trials)

autologous adipose-derived mesenchymal stem cells (1 trial)

azithromycin (zithromax) (4 trials)

bortezomib (velcade) (1 trial)

corn (3 trials)

dihydroartemisinin (1 trial)

docetaxel (taxotere) (3 trials)

esomeprazole (nexium) (1 trial)

insulin human (humulin) (1 trial)

norgestrel (Ovral) (1 trial)

pyrimethamine (daraprim) (1 trial)

sitagliptin (januvia) (1 trial)

soybean (1 trial)

sulfadoxine (2 trials)

testosterone (delatestryl) (1 trial)

timolol (blocadren) (1 trial)

toremifene (fareston) (2 trials)

urea (4 trials)

Drugs in Phase 2 Trials (23)

allogeneic adipose derived mesenchymal stem cell (2 trials)

anakinra (Kineret) (1 trial)

azathioprine (imuran) (1 trial)

bevacizumab (avastin) (1 trial)

bl-7010 (1 trial)

cabazitaxel (jevtana kit) (1 trial)

celecoxib (celebrex) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

disodium pyrophosphate (1 trial)

etoposide (vepesid) (1 trial)

hexyl 5-aminolevulinate (Cysview) (1 trial)

Hydroxyflutamide (1 trial)

latiglutenase (2 trials)

leflunomide (arava) (1 trial)

leuprolide (lupron) (1 trial)

liraglutide (victoza) (3 trials)

platelet-rich plasma (1 trial)

prv-015 (1 trial)

sargramostim (leukine) (1 trial)

sodium phosphate (1 trial)

thalidomide (Thalomid) (1 trial)

venetoclax (venclexta) (1 trial)

verecimon (1 trial)

Drugs in Phase 1 Trials (4)

aeras-404 (1 trial)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV) (1 trial)

cis-urocanic acid (1 trial)

nitrous oxide (1 trial)

Drugs in Other Trials (16)

amoxicillin (1 trial)

barley starch (1 trial)

cefuroxime (zinacef) (1 trial)

ertapenem (invanz) (4 trials)

fluticasone (cutivate) (1 trial)

human fecal microbiota (Reybota) (1 trial)

levobupivacaine (chirocaine) (1 trial)

levofloxacin (levaquin) (1 trial)

magnesium (1 trial)

metronidazole (flagyl) (1 trial)

moxifloxacin (avelox) (2 trials)

oxygen (1 trial)

theophylline (synophylate) (1 trial)

vitamin d3 (4 trials)

whole blood (1 trial)

whole wheat allergenic extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abortion, Spontaneous (Phase 3)

Acute Kidney Injury (Phase 4)

Anaphylaxis (Phase 4)

Arthritis (Phase 4)

Arthritis, Juvenile (Phase 2)

Arthritis, Rheumatoid (Phase 4)

Atrial Fibrillation (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Celiac Disease (Phase 2)

Cerebral Hemorrhage (Phase 4)

Chronic Pain (Phase 4)

Communicable Diseases (Phase 4)

Contracture (Phase 4)

Diabetes, Gestational (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Dupuytren Contracture (Phase 4)

Embolism (Phase 4)

Enterovirus Infections (Phase 1)

Erectile Dysfunction (Phase 3)

Genital Diseases, Female (Phase 4)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Growth Disorders (Phase 3)

Head and Neck Neoplasms (Phase 4)

Heart Valve Diseases (Phase 4)

Hemorrhage (Phase 4)

Hutchinson's Melanotic Freckle (Phase 4)

Hypersensitivity (Phase 4)

Hypertension (Phase 4)

Hypoglycemia (Phase 4)

Hypogonadism (Phase 3)

Infections (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Insulin Resistance (Phase 4)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Lentigo (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)

Malaria (Phase 3)

Malnutrition (Phase 3)

Mastodynia (Phase 3)

Menorrhagia (Phase 3)

Milk Hypersensitivity (Phase 4)

Mucositis (Phase 2)

Multiple Myeloma (Phase 3)

Myocardial Stunning (Phase 4)

Neoplasms, Basal Cell (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Ocular Hypertension (Phase 4)

Opioid-Related Disorders (Phase 4)

Pain, Postoperative (Phase 4)

Pancreatitis (Phase 2)

Polycystic Ovary Syndrome (Phase 3)

Postoperative Complications (Phase 2)

Postoperative Nausea and Vomiting (Phase 4)

Prediabetic State (Phase 1)

Pregnancy in Diabetics (Phase 4)

Premature Birth (Phase 3)

Prostatic Neoplasms (Phase 4)

Pseudoxanthoma Elasticum (Phase 2)

Pulmonary Embolism (Phase 4)

Sexually Transmitted Diseases (Phase 3)

Signs and Symptoms (Phase 4)

Still's Disease, Adult-Onset (Phase 2)

Stomatitis (Phase 2)

Stroke (Phase 1)

Syndrome (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Toxemia (Phase 3)

Tuberculosis (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Urinary Tract Infections (Phase 4)

Venous Thromboembolism (Phase 4)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 112
  • # of Trial APIs: 115